Drug Profile
GR 1401
Alternative Names: GR1401Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Genrix (Shanghai) Biopharmaceuticals
- Developer 307th Hospital of Chinese Peoples Liberation Army; Genrix (Shanghai) Biopharmaceuticals
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in China (Parenteral)